Six melanoma specialists said the Moderna and Merck vaccine results represent a clinically meaningful advance in melanoma ...

Merck CEO Rob Davis joins 'Squawk on the Street' to discuss leaked data of melanoma vaccine trials, the drop off the ...

Leaked data from Moderna Inc. and Merck & Co.’s highly anticipated melanoma vaccine trial has led to a rare disconnect ...

Merck KGaA agreed to acquire Silence Therapeutics Plc for about $1.1 billion in a cash transaction as the German science ...

Merck reports Q3 earnings on Oct. 29 with KEYTRUDA's 2028 patent clock ticking louder, and whether LIPFENDRA, QLEX, and ...

Merck (MRK) stock returned 78.7% in the twelve months to October 21, 2026, against 16.5% for the S&P 500. Over that year, ...

The $20-per-ADS all-cash acquisition agreement follows Phase 2 progress for Divesiran and is expected to close in the first ...

TMT, has shown a strong tumor progression benefit in first-line, PD-L1-negative non-small cell lung cancer in a China phase 3 ...

Executive SummaryHow to Interpret Two Premiums and Explain the Acquisition Price of a Loss-Making Company (Merck's ...

Moderna's personalized melanoma vaccine just posted positive late-stage results alongside Merck, yet shares keep sliding ...

Merck stock looks fairly valued as Keytruda risks, slower EPS growth, and debt weigh on upside. Click here to read an ...

A combination of the shot and the immunotherapy Keytruda cut the risk of relapse or death by 42% in a landmark melanoma study that met Wall Street expectations but triggered a “sell-the-news reaction, ...